Early Use of Novel Biologics in Psoriatic Arthritis: An Evolving Standard of Care

Hear expert insights on when to use interleukin inhibitors in the course of psoriatis arthritis. Review key data on using these novel agents for DMARD-refractory disease with an on-demand expert presentation and focused commentary.
Vinod Chandran, MBBS, MD, DM, PhD
person default
Alexis Ogdie, MD, MSCE

Video Module

Hear expert insights on when to use interleukin inhibitors in the course of psoriatic arthritis.

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 29, 2020 Expired: December 28, 2021

Review key data on when to use interleukin inhibitors in the course of psoriatic arthritis.

Vinod Chandran, MBBS, MD, DM, PhD person default Alexis Ogdie, MD, MSCE Released: December 29, 2020
Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue